Last Updated : May 4, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort ascending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Alecensaro | alectinib | ALK-positive NSCLC | Received | |||
Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Received | |||
TBC | rozanolixizumab | Generalized myasthenia gravis (gMG). | Pending | |||
Vanflyta | quizartinib | acute myeloid leukemia (AML) | Pending | |||
N/A | enzalutamide | Genito-urinary cancer (prostate cancer) | Pending | |||
Spevigo | spesolimab | generalized pustular psoriasis (GPP) | Pending | |||
TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Pending | |||
Tafinlar-Mekinist | dabrafenib trametinib | Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation | Pending | |||
Ferinject | ferric carboxymaltose | Iron deficiency in adult patients with heart failure | Pending | |||
Ferinject | ferric carboxymaltose | Iron deficiency anemia | Pending |